Description

BPC-157 Peptide

 

CAS Number	137525-51-0
Other Names	BPC157, BPC 157, Bepecin, 8ED8NXK95P, Bpc 15, PLD-116, PL-14736, pl-10, Booly protection compound 15
IUPAC Name	(4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxopentanoic acid
Molecular Formula	C₆₂H₉₈N₁₆O₂₂
Molecular Weight	1419.5
Purity	≥99% Pure (LC-MS)
Liquid Availability	5mL liquid spray solution (includes 5 milligrams of peptide)
Powder Availability	5 milligrams (lyophilized/freeze-dried) 60 capsules (250mcg/capsule, 15mg (15,000mcg) total bottle)
Storage Condition	Store cold, keep refrigerated. Do NOT freeze.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

**Important Information: Each peptide comes lyophilized/freeze-dried and must be reconstituted with Bacteriostatic Water in order to be dispensable in liquid form.

Watch How To Reconstitute Peptide Video Here

What is BPC 157?

BPC 157 is characterized as a pentadecapeptide containing partial sequence of the body protection compound (BPC) that is shown to have had positive effects on the efficiency and efficacy of various growth hormones as well as various other healing qualities in cases such as spinal cord injury and burn wounds.

3 Main Research Findings

1) Application of BPC 157 improved the burn-wound healing ability of mice while attenuating burn-gastric lesions.

2) Administration of the peptide BPC 157 enhances the expression of growth hormone receptors in tendon fibroblasts.

3) Evidence shows that administering BPC 157 to rats improves the healing rate of spinal cord injury while enhancing functional recovery.

Selected Data

1) The research team of Mikus et. Al examined the effects of topical application and intraperitoneal application of the BPC 157 on burn-wound healing burn-gastric lesions. The peptide was acquired as a 99% pure substance that was further dissolved in saline prior to the random assignment of male mice to an experimental treatment. All subjects were housed in individual cages with ad libitum access to food and water. Each experimental treatment group included 10 mice. While sedated under ether anesthesia, deep partial skin thickness burns were induced on the back of each test subject through the method of control burning. The first application of the peptide was given immediately after the burn-injury. 50 ug of BPC 157 was either dissolved in 2 ml of distilled water or mixed with 50 g of a commercial neutral cream to be applied in a line layer over the burn. Similarly, 10 ug or 10ng/kg of BPC 157 was also administered to a group of test subjects through an intraperitoneal injection. Additionally, an equal amount of neutral commercial cream or saline was topically and intraperitoneally administered to the test subjects in order to act as a vehicle-control [1].

The burn healing parameter was evaluated through various forms of histological investigation, water content assessment in the burned skin, and tensiometry studies such as breaking strength and elongation of the burned skin. The same methods were used to assess the status of the induced gastric lesions; all assessments were completed on either day 1, 2, 3, 7, 14, or 21. The histological assessment used to investigate the healing parameters of the mice included edema, formation of blood vessels, retained follicles, formation of reticulin and collagen, number of inflammatory cells, and the number of subjects experiencing complete re-epithelialization. The healing parameters were tested on different days following euthanization of the animals. The schedule is as follows: day 1: edema, diameter and number of blood vessels, number of inflammatory cells and reticulin, and number of vital follicles; day 2 and 3: day 1 necrosis; day 14: number and diameter of blood vessels, reticulin and collagen levels, epithelization; day 21; number and diameter of blood vessels, epithelization and collagen.

When assessing the water content of the burned sites, the researchers initially began by conducting a separate experiment that included a 20×20 mm specimen of full-thickness tissue originating from the burned sites of the back. Additionally, a 20×20 mm specimen was extracted from the non-damaged tissue of the upper back for the purpose of weight determination at days 1, 2, and 3 following euthanization. All tissue biopsies were placed in a drying chamber until a stable weight was measured for approximately 48 hours. The research team then calculated the wet/dry ratio of each specimen in order to compare them to the values of the control groups. Tensiometry investigation took place by measuring the tensile breaking force and relative elongation of the damaged skin immediately after euthanasia and at days 7 and 14. A special device obtained from the Technical Faculty at the University of Zagreb, Croatia using the formulas: breaking force (N/mm2)=force (N)/cross-section skin burned area (mm2); and relative elongation of burned part of skin=Δlength burned skin immediately before breaking/initial length of burned skin. This protocol was followed by statistical analysis completed by Fisher’s exact probability test two-tailed and one-way ANOVA [1].

2) The research team of Chang et. Al examined the effects of BPC 157 on the expression of growth hormones and how it can potentially activate fibroblast proliferation and keratinocyte migration. Growth hormones are peptides that stimulate growth, cell reproduction, and regeneration of chondrocytes and osteoblasts, as well as increase protein production and muscle mass. The study utilized male Sprague-Dawley rats as their source of tendon fibroblasts; the achilles tendons were harvested by aseptic procedures followed by dissection into pieces at size about 1.5 to 2.0 mm^3 and separation into six-well culture plates. After migrating out from the explants, the tendon fibroblasts began to grow rapidly. Once the samples reached confluency the cells were subcultured and all tendon fibroblasts between passages 2 and 4 that had a proper growth rate and normal fibroblast shape were used in the experimentation process. From there, BPC 157 synthesized and purchased from Kelowna International Scientific Inc. was added to the fibroblasts at concentrations of ) (control group), 0.1, 0.25, and 0.5 ug/mL and incubated in a humidified atmosphere for 1, 2, and 3, days [2].

The next experimental step included extracting total RNA from the cells through the use of the acid guanidinium thiocyanate-phenol-chloroform extraction method. Total RNA was then used to synthesize complementary DNA, followed by the performance of real-time PCR using an SYBR Green I technology and MxPro-Mx3000P QPCR machine. All real-time PCRs were performed three times and all changes in gene expression were reported as multiples of increases relative to the control while GAPDH was used as an internal control and relative gene expression between the experimental groups were determined using MxPro software.
Furthermore, western blot analysis took place by initially preparing cell extracts in a lysis buffer followed by the standard method of ultrasonication. The Bradford assay was used to determine protein concentration of cell extracts, from there samples with the same amount of protein were separated using SDS-PAGE technology and transferred onto a PVDF membrane. The membrane was then incubated at room temperature in blocking solution for 1 hour, followed by incubation in blocking solution containing the appropriate dilution of either phospho-Jak2 or the primary antibody for growth hormone receptor, for 2 hours. The membrane was washed three times in PBS prior to 1 hour of incubation in PBS containing goat anti-mouse IgG conjugated with horseradish peroxidase. After an additional three washings with PBS, positive signals were developed with an enhanced chemiluminescence kit [2].

An MTT assay was performed next by seeding tendon fibroblast in each well of 24-well culture plates. In addition to a medium made of 0.5 ml of DMEM, 10% FBS, 100 U/mL of penicillin, and 100 mg/mL of streptomycin, BPC 157 was added to each well in concentrations of 0 (control group), 0.1, 0.25, and 0.5 ug/mL for 1, 2, and 3 days in a humidified atmosphere. One day after growth hormone was added to the tendon fibroblasts treated with BPC 157, the cells were washed with PBS followed by the addition of 1 mL DMEM containing 0.05 mg/mL MTT,, and incubation for 1 hour. The media was then removed and the formazan crystals that formed during incubation were dissolved in 1 mL DMSO and processed for OD reading.

3) The research team of Pervoic et. Al studied the effectiveness of BPC 157 treatment when healing spinal cord injuries and how the peptide promotes functional recovery in test subjects. This study included 12 week-old Wistar albino male rats that were bred in-house at the animal facility at the Department of Pharmacology, School of Medicine in Zagreb, Croatia. The animals were allowed to acclimate to their new environment over the course of 5 days, followed by random assignment to an experimental treatment group. At least 6 animals were included in each group and all test subjects were maintained under standard conditions including a 12 hour light/12 hour dark schedule as well as ad libitum access to a standard GLP diet and fresh water. BPC 157 was dissolved in 0.9% NaCl and underwent further preparation with 99% high-pressure liquid chromatography (HPLC).

The animals were then deeply anesthetized with 3% isoflurane and 50 mg/kg of ketamine followed by a laminectomy at lumbar level L2-L3, corresponding to the sacrocaudal spinal cord. A 200 ug/kg or 2 ug/kg dose of BPC 157 was intraperitoneally injected 10 minutes post-injury followed by the return of animals to their cages and assignment to interval groups varying from days 7, 15, 20, 90, 180, and 360. The tail motor function of each test subject was scored 8 hours and 1, 4, 7, 15, 30, 90, 180, and 360 days post-injury and measured on a scale of 0-5. 0 was defined as autotomy; 1-complete loss of tail function; 2-maximum elevation of ¼ of the tail; 3-maximum elevation of ½ of the tail; 4-maximum elevation of ¾ of the tail; and 5 was defined as normal functioning of tail motor control. The same intervals were used when assessing tail spasticity. Manual stimulation of the tails was performed next using the standardized stretch/rub maneuver followed by scoring according to the Bennett scale. 0 on the Bennett scale is defined as a normal phenotype; 1-flaccid tail; 2-hypertonic flexor muscle, tail coiled and stiff; 3- hyperreflexia; and 4 is defined as hypertonic flexor and extensor muscles [3].

Prior to euthanization, the animals from the 30, 90, 190, and 360 day post-injury interval groups were placed in a wooden box that allowed for tail exposure. This was followed by three pairs of monopolar needles stabbed 3 mm deep into the tail at measurements of 10, 60, and 100 mm caudal to the base of the tail. From there the voluntary muscle activity was recorded from the most caudal pair of electrodes, followed by measurement and recording of the average motor unit potential (UMP) and the compound motor action potential (CMAP). CMAP was recorded after stimulating the first and second electrodes followed by recording of the amplitude, proximal and distal latencies, and polyphasic changes. Following the electrophysiological testing, histology testing took place by initially collecting a 10-mm long piece of the spinal column and the surrounding muscle. After 5 um cross-sections were prepared according to procedure, the intensity and distribution of the pathological spinal cord changes were evaluated semiquantitatively. In this study 0 was defined as no changes; 1-small or focal changes; 2-moderate changes; and 3-numerous confluent changes subcategorized into: (a) the hemorrhagic zone, (b) edema, (c) the loss of neurons, (d) vacuoles, and (e) the loss of spinal column tracts [3].

Discussion

1) The results of the study found that mice treated with only a cream vehicle showed no difference in healing parameters with respect to the control groups treated with saline only. However, application of the BPC 157 cream resulted in an improvement in all healing parameters measured throughout the experiment. There was less edema observed and lower levels of inflammatory cells present; the rate of necrosis was decreased while the number of capillaries, dermal reticulin, and collagen fiber all significantly increased. By day 14 the mice treated with BPC 157 cream had experienced a complete reversal of the poor re-epithelization ratio that was noted in the control mice. The secondary studies regarding the efficacy of silver sulfadiazine cream, as well as an intraperitoneal injection of BPC 157, were not as successful as the primary research investigating the burn-healing properties of BPC 157 cream. In the mice treated with silver sulfadiazine only collagen fiber formation was increased while the mice intraperitoneally injected with BPC 157 only experienced a reduction in the number of inflammatory cells, but all other parameters remained unchanged [1].

In regards to water content, cream-vehicle treatment resulted in no changes in the mice subject to direct flame for 5 or 7 seconds. However, when the test subjects were treated with BPC 157 cream a lower water content was measured. Treatment with BPC 157 in the mice exposed to direct flame for 5 seconds, resulted in decreased water content by day 1 post-injury. Tensile breaking force was measured next in the mice subjected to direct flame for 5 seconds. At days 7 and 14 post-injury, the tensile breaking force portrayed higher values in the test subjects treated with a topical cream form of BPC 157; at day 14, higher tensile breaking force values were noted in the mice administered BPC 157. The positive results were not identified in any of the control groups. Similarly, the mice subjected to direct flame for 7 seconds experienced no enhancement of tensile breaking force when treated with any of the control treatments. However, topical administration of BPC 157 led to a significant increase in tensile breaking force. Because the peptide was still shown to be effective 14 days post-injury, the researchers suggested that there is increased activity of wound healing mechanisms to increase mechanical strength, as well as an increase in potentiated activity that could lead to beneficial results. Similar results were found when measuring relative elongation of the burned part of the skin in the mice subjected to direct flame for both 5 and 7 seconds [1].

Figure 1: Changes in breaking tensile force and relative elongation of the burned part of skin in response to different experimental treatments.

2) Results of the cDNA microarray performed by the research team in a previous study, revealed that expression of the growth hormone receptor genes was significantly increased in the tendon fibroblasts treated with BPC 157. In order to confirm the previous finding BPC 157 was administered in varying concentrations and incubated for 24 hours in order to examine the effects of the peptide in different doses. When administered at doses of 0, 0.1, 0.25, and 0.5 ug/mL, growth hormone receptor expression was increased in a dose-dependent manner. Additionally, the results reported that when administering BPC 157 in concentrations of 0.5 ug/mL, growth hormone expression in the tendon fibroblasts was induced in a time-dependent manner from day 1 to day 3. It is also important to mention that RNA and protein levels were determined by real-time PCR and Western blotting, respectively. By day 3 a seven-fold increase in RNA and protein levels could be observed [2].

Figure 2: changes in growth hormone expression in a (A) dose-dependent manner and (B) a time-dependent manner.

Because the binding mechanism of growth hormone has shown the potential to trigger the activation of signaling pathways and cell proliferation, the research conducted a secondary study that included adding growth hormone to tendon fibroblasts already treated with BPC 157. Following treatment with varying concentrations of BPC 157 and 24 hours of incubation, the cells were administered 0.1 ug/mL of growth hormone and incubated for an additional 24 hours in order to accurately measure cell viability by MTT assay. The amount of viable cells increased in a dose-dependent manner following the addition of growth hormone. In a similar manner to the primary study, the number of viable cells significantly increased from day 1 to day 3 when 0.1 ug/mL of growth hormone was applied to the cells. In order to further solidify their findings, the researchers analyzed the expression of the cell proliferation marker and the proliferating cell nuclear antigen (PCNA) in tendon fibroblasts at the RNA expression level through the use of RT-PCR. The results revealed that there was a similar pattern of PCNA induction by administration of BPC 157 and growth hormone, that correlated with the increase in the number of viable cells [2].

Figure 3: Changes in the number of viable cells in the BPC 157-treated tendon fibroblasts following the addition of growth hormone

Figure 4: Changes in PCNA gene expression in the BPC 157-treated tendon fibroblasts following the addition of growth hormone

3) The results of the study conducted by the research team of Pervoic et. Al first ensured that the rats that underwent spinal cord injury demonstrated the proper level of debilitation. From there, it was found that treatment with BPC 157 in the experimental groups led to consistent improvement in motor function in comparison to the control groups. It is important to mention that by day 180 post-injury autotomy was observed in the rats that underwent spinal cord injury but did not receive peptide treatment. When examining the effects of BPC 157 on tail spasticity the results reported that development of spasticity began earlier in the test subjects treated with the peptide in comparison to the corresponding controls. The rats treated with BPC 157 exhibited resolved tail spasticity by day 15 post-injury while the rats in the control group did not exhibit sustained spasticity until day 360 [3].

Figure 5: Changes in tail motor function in response to treatment with BPC 157

Figure 6: Changes in tail spasticity in response to treatment with BPC 157

The results of the electrophysiology testing suggested that the rats subjected to EMG recordings after surgical spinal cord surgery and treatment with BPC 157, exhibited a significantly lower MUP in the muscles of the tail than was observed in the control group. The motor nerve conduction study also confirmed the absence of unmyelinated processes in the tail caudal nerves following surgical spinal cord injury. On the other hand, the CMAP portrayed normal biphasic potentials and similar amplitudes and conduction velocities. Additionally, the histology results found that 10 minutes post-injury a large hemorrhagic zone was observed over the white columns in the test subjects, but no change in the gray matter. By day 7 the control groups began to show vacuoles and loss of spinal column tracts where the hemorrhagic areas should have been. Loss of neurons and increased edema in the anterior horn and gray matter was also observed in the control groups, however, all rats treated with BPC-157 were able to counteract the disturbances [3].

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Citations

[1] Mikus D, Sikiric P, Seiwerth S, Petricevic A, Aralica G, Druzijancic N, Rucman R, Petek M, Pigac B, Perovic D, Kolombo M, Kokic N, Mikus S, Duplancic B, Fattorini I, Turkovic B, Rotkvic I, Mise S, Prkacin I, Konjevoda P, Stambuk N, Anic T. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 2001 Dec;27(8):817-27. doi: 10.1016/s0305-4179(01)00055-9. PMID: 11718984.

[2] Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. doi: 10.3390/molecules191119066. PMID: 25415472; PMCID: PMC6271067.

[3] Perovic, D., Kolenc, D., Bilic, V. et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res 14, 199 (2019). https://doi.org/10.1186/s13018-019-1242-6

 

PEPTIDES PREFER THE COLD
Keep peptide vials refrigerated at all times to reduce peptide bond breakdown. DO NOT FREEZE. Most peptides, especially shorter ones, can be preserved for weeks if careful.
Always swab the top of the vial with an alcohol wipe or rubbing alcohol before accessing.
ONLY MIX WITH STERILE BACTERIOSTATIC WATER
The purity and sterility of bacteriostatic water are essential to prevent contamination and to preserve the shelf-life of dissolved peptides.
Push the pin through the rubber stopper at a slight angle, so that you inject the bacteriostatic water toward the inside wall of the vial, not directly onto the powder.
Lyophilized peptide should be stored at -20°C (freezer), and the reconstituted peptide solution at 4°C (refrigerated). Do not freeze once reconstituted.

BPC-157 is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

BPC-157 – Investigating The Peptide’s Role In Cellular And Tissue Repair

 

 

 

 

 

 

File Name	View/Download
09-21-2023-Umbrella-Labs-BPC-157-Certificate-Of-Analysis-COA.pdf

 

VIEW CERTIFICATES OF ANALYSIS (COA)

Additional information

Weight	1 oz
Dimensions	0.5 × 0.5 × 1 in
Options	60 Capsules, Peptide With Liquid Spray Solution, 5 Milligrams Vial